International generic pharmaceuticals company Actavis has announced the launch of a product used in the treatment of schizophrenia and bi-polar disorder in Germany.

The product is sold through Actavis' third party division, Medis, to other pharmaceutical companies which market the product under their own label. Medis' customers are the first to market a generic version of this product in Germany.

The Actavis product was developed at Actavis' principal research and development site in Iceland, and is manufactured in Actavis' production plant in Malta for the German market. The fact that Actavis completed the development of the product very early, five years prior to patent expiry, made it possible for the company to seize this opportunity. The company's regulatory affairs staff and the production staff in Malta worked very hard to make the launch possible at this early stage.

Actavis Ltd is a subsidiary of the Actavis Group, a multinational pharmaceutical organisation employing 11,000 people in 40 countries worldwide. The Maltese operation boasts a workforce of 450 highly skilled employees.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.